Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B

Tempus AI, Inc.

2026-Q1 EPS reported -$0.71 vs consensus -$0.19 ▼ miss (-266.9%)

Revenue $348.1M, +36% YoY; Diagnostics $261.1M (+34.7%), Data & Apps $87.0M (+40.5%).
Net loss $(125.9)M vs $(68.0)M YoY, includes $56.3M stock comp and $32.3M unrealized securities losses.
Adjusted EBITDA $(2.8)M, improved from $(16.2)M in Q1 2025.
Raised FY2026 revenue guidance to $1.59-1.60B (~25% annual growth); maintains ~$65M Adj. EBITDA outlook.
MRD test volume ~6,500, up ~500% YoY; expanded collaborations with Merck, Gilead, Northwestern Medicine.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempus AI, Inc. reported the quarter ended March 31, 2026 results: revenue $348.1 million, net income ($125.9 million), EPS ($0.70). Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $348.1 million
Net income: ($125.9 million)
EPS: ($0.70)
Guidance: raised
Result: reported results

Exact text from the filing

technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. • Revenue of $348.1 million, up 36.1% year-over-year • Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% • MRD volume was ~6,500 tests

View on SEC.gov

Browse all earnings releases →

Tempus AI, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.